Restless Legs Syndrome - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Restless Legs Syndrome - Pipeline Review, H2 2015’, provides an overview of the Restless Legs Syndrome’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Restless Legs Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Restless Legs Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Restless Legs Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Restless Legs Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Restless Legs Syndrome - Overview 7
Pipeline Products for Restless Legs Syndrome - Comparative Analysis 8
Restless Legs Syndrome - Therapeutics under Development by Companies 9
Restless Legs Syndrome - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Restless Legs Syndrome - Products under Development by Companies 13
Restless Legs Syndrome - Companies Involved in Therapeutics Development 14
Alexza Pharmaceuticals, Inc. 14
Ascendis Pharma A/S 15
Hisamitsu Pharmaceutical Co., Inc. 16
Ligand Pharmaceuticals, Inc. 17
Mundipharma International Ltd 18
Omeros Corporation 19
Serina Therapeutics, Inc. 20
Vifor Pharma AG 21
Restless Legs Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 31
(naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
aplindore fumarate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AZ-008 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ferric carboxymaltose - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OMS-527 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pramipexole dihydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ropinirole hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SER-214 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Restless Legs Syndrome - Recent Pipeline Updates 40
Restless Legs Syndrome - Dormant Projects 42
Restless Legs Syndrome - Discontinued Products 43
Restless Legs Syndrome - Product Development Milestones 44
Featured News & Press Releases 44
May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs 44
Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome 45
Jan 07, 2014: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome 45
Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome 46
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List Of Tables
Number of Products under Development for Restless Legs Syndrome, H2 2015 7
Number of Products under Development for Restless Legs Syndrome - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Restless Legs Syndrome - Pipeline by Alexza Pharmaceuticals, Inc., H2 2015 14
Restless Legs Syndrome - Pipeline by Ascendis Pharma A/S, H2 2015 15
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2015 16
Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 17
Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H2 2015 18
Restless Legs Syndrome - Pipeline by Omeros Corporation, H2 2015 19
Restless Legs Syndrome - Pipeline by Serina Therapeutics, Inc., H2 2015 20
Restless Legs Syndrome - Pipeline by Vifor Pharma AG, H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Assessment by Combination Products, H2 2015 23
Number of Products by Stage and Target, H2 2015 25
Number of Products by Stage and Mechanism of Action, H2 2015 27
Number of Products by Stage and Route of Administration, H2 2015 29
Number of Products by Stage and Molecule Type, H2 2015 30
Restless Legs Syndrome Therapeutics - Recent Pipeline Updates, H2 2015 40
Restless Legs Syndrome - Dormant Projects, H2 2015 42
Restless Legs Syndrome - Discontinued Products, H2 2015 43
List Of Figures
Number of Products under Development for Restless Legs Syndrome, H2 2015 7
Number of Products under Development for Restless Legs Syndrome - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Top 10 Targets, H2 2015 24
Number of Products by Stage and Top 10 Targets, H2 2015 24
Number of Products by Top 10 Mechanism of Actions, H2 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 26
Number of Products by Top 10 Routes of Administration, H2 2015 28
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 28
Number of Products by Stage and Top 10 Molecule Types, H2 2015 30
